Connected data gives you a clearer picture
At Evaluate we collect, calibrate and connect the pharmaceutical world's data.
Thought Leadership
Latest Report
ASH Preview 2023: Ones to Watch
The American Society of Hematology (ASH) Annual Meeting and Exposition is the last big clinical conference of the year. As we head into 2024, which areas are set to attract investment with their latest datasets, and which are in danger of falling flat? ASH will see the latest data reveals on CAR-T products, multiple myeloma, leukaemia and…
Report library
ASCO 2023 Round Up
The Evaluate Vantage team are back from the 2023 ASCO Annual Meeting in Chicago, where we've been reporting on all the big data drops and breakthroughs in cancer…
Biopharma Dealmaking In 2023: The Story So Far
Bio International marks the almost-halfway stage of the year. Representatives from big pharma, single-asset biotechs and everyone in between come together to meet, learn…
Pharma’s Biggest Spenders 2022 Infographic
As several of the big 11 pharma companies dialled back on acquisitions, the collective bill for M&A and R&D activities among this cohort took a dip for the second…
Gene Editing: Overhyped or Unstoppable Tide?
It’s a decade since Crispr first hit the headlines and now the first product using the approach is on the verge of approval. By pharma standards, this is breakneck speed…
Q1 2023 Round Up: And so it continues...
2022 was a rough year for much of the pharma sector, with limited M&A, IPO, and venture financing activity. With Q1 now over, are we expecting to see an improvement…
Quarter 1 Round up 2023 Infographic
Pharma has had a tough go of it over the past year, with limited M&A, IPO, and venture financing activity. As Q1 draws to a close, many are wondering if the sector is…
CROI 2023 article pack
Thanks to the forum it provides the Conference on Retroviruses and Opportunistic Infections (CROI) has helped to facilitate the accelerating progress in HIV and AIDS…
Pharma Drivers: Money for Nothing
This eBook analyses the routes biotech companies are taking to gain access to public markets. While Spacs had their moment in the sun, they are now widely perceived as a…
Orphan Drugs 2023-2028: A flattening curve?
300 million people around the world live with a rare disease. This perhaps explains the seemingly endless growth of orphan drugs and the forecasted $300bn market by…
Orphan Drugs 2023-2023: Is the shine coming off?
After a decade of outpacing the market, are we finally going to see a plateau in the growth of orphan drugs? Well, maybe. Data-wise, there’s only a hint of that being the…